United States of America– [28-January-2026]

The global bioproduction market is undergoing a period of rapid expansion due to rising demand for biologics, biosimilars, vaccines, cell and gene therapies, and nucleic acid therapeutics.

Market Size ,Share And Trends

According to the  latest industry research , bioproduction market was valued at approximately US 22.34 billion in 2022 and is expected to reach US 63.39 billion by 2030. CAGR of about 13.9 %. The various segments of the market reveal important trends in both technology adoption and end user needs.

Get A Pdf Copy@ https://www.theinsightpartners.com/sample/TIPRE00030322

Key Growth Drivers

One of the major drivers of bioproduction industry growth is the increasing patent expiry of blockbuster biologicals. When patents for well established biologic therapies expire, there is heightened demand for biosimilars as cost effective alternatives. The transition from reference molecules to biosimilars is encouraging bioproduction capacity expansion worldwide. As more manufacturers enter the sector, competition intensifies and investment in capacity and process improvements becomes more pronounced

Industry Developments and Future Opportunities

• In March 2023, Lonza Group AG announced the completion of its cGMP clinical and commercial drug product production line in Visp, Switzerland. The facility is designed to serve customers with a wide range of production requirements, supporting both clinical and commercial supply.
• In May 2022, FUJIFILM Irvine Scientific Inc completed its Innovation and Collaboration Center in Suzhou New District, China. As a leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy, the company aims to leverage this center to collaborate closely with customers and partners

Frequently Asked Questions

1.What role do gene and cell therapies play in market expansion?
A: Gene and cell therapies represent high-growth segments because they offer innovative treatment options for genetic disorders and cancers, increasing the need for complex manufacturing processes.

2. Which regions are leading the bioproduction market?
   A: North America dominates the market due to strong research and healthcare infrastructure, while Asia Pacific is the fastest-growing region driven by rising biotech investments and supportive policies.
3. How are biosimilars influencing the bioproduction industry?
   A: Biosimilars are improving affordability and accessibility of biologic treatments, encouraging pharmaceutical companies to invest in scalable and cost-efficient bioproduction technologies.

Market Segmentation Analysis

By Product

The bioproduction market is categorized based on the type of product being manufactured. Each product segment has unique growth drivers, technological requirements, and market potential:

• Biologics and Biosimilars: This segment includes therapeutic proteins, monoclonal antibodies, and other biological medicines. In 2022, it held the largest market share due to high global demand and the upcoming patent expirations of blockbuster biologics.
• Vaccines: This includes preventive and therapeutic vaccines. Vaccine production requires high-volume, sterile bioprocessing, which is driving demand for advanced equipment and automation.
• Cell and Gene Therapies: These are rapidly growing segments. Cell therapy modifies or restores cells to treat disease, while gene therapy corrects or introduces genes. Both therapies are driving demand for specialized bioproduction platforms and automated workflows.
• Nucleic Acid Therapeutics: Includes RNA and DNA-based therapies, such as mRNA vaccines and antisense therapies. These products require precise manufacturing processes and controlled environments.

By Application

Applications indicate the therapeutic areas where bioproduction products are used:

• Rheumatoid Arthritis: Biologics and biosimilars for autoimmune disorders.
• Hematological Disorders: Products addressing blood-related diseases.
• Cancer: The largest application segment, driven by high demand for oncology biologics and biosimilars. Biologics can directly target cancer cells, enhance immune response, and manage chemotherapy side effects.
• Diabetes: Bioproduction of insulin analogs and supportive therapeutics.
• Cardiovascular Diseases: Includes biologics for heart conditions.

By Equipment

Equipment segmentation reflects the tools and machinery required in bioproduction processes:

• Upstream Equipment: Includes bioreactors and cell culture systems used in the initial stages of production.
• Downstream Equipment: Involves purification, filtration, and formulation machinery.
• Bioreactors: Specialized vessels for cultivating cells or microorganisms at various scales.
• Consumables and Accessories: Includes flasks, pipettes, filters, and media. This segment held the largest share in 2022 and is growing rapidly due to recurring demand in daily operations.

By End User

End user segmentation identifies who is consuming the bioproduction products or services:

• Biopharmaceutical Companies: The largest segment, including companies producing biologics, vaccines, and cell therapies for commercial sale.
• Contract Manufacturing Organizations (CMOs): Outsourced manufacturers offering scalable production, which is projected to grow at the highest CAGR.

Regional Analysis

North America leads the global bioproduction market, supported by robust infrastructure, high healthcare spending, and a large base of ongoing research activities. The United States in particular has a strong regulatory environment that supports biosimilar approvals and cell therapy development. Asia Pacific is expected to register the fastest growth due to increasing investments in healthcare, expanding research and development activities, and favorable regulatory reforms that promote bioproduction expansion.

Key Players in the Bioproduction Market

• Thermo Fisher Scientific Inc
• Merck KGaA
• F. Hoffmann‑La Roche Ltd
• Bio‑Rad Laboratories Inc
• Lonza Group AG
• bbi‑biotech GmbH
• Danaher Corp
• Sartorius AG
• FUJIFILM Irvine Scientific Inc

These organizations are actively involved in expanding their portfolios through innovation, strategic partnerships, and capacity expansions.

Future Outlook

Looking ahead, the bioproduction market is poised for sustained growth as therapeutic innovation continues. Increased adoption of personalized medicine, growth in global biosimilar demand, and improvements in digital manufacturing technologies will shape how bioproduction facilities operate. Investment in next generation manufacturing infrastructure is expected to accelerate, particularly in emerging regions. Regulatory harmonization and incentives for advanced therapy medicinal products will further support market expansion. As manufacturing processes become more efficient and standardized, bioproduction will play a central role in ensuring global access to advanced biologic treatments for a wide range of diseases.

About The Insight Partners

The Insight Partners delivers market intelligence and consulting services to help clients make informed decisions. The firm covers industries such as Aerospace and Defense, Automotive and Transportation, Semiconductor and Electronics, Biotechnology, Healthcare IT, Manufacturing, Medical Devices, Technology, Media, and Chemicals and Materials.

Contact Information:
Email: [email protected]
Website: www.theinsightpartners.com
Phone: +1-646-491-9876

Also Available in :

Korean German Japanese French Chinese Italian Spanish